Z. Alexander Cao

Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study

Michael J. Overman, Ray McDermott, Joseph L. Leach et al. · The Lancet Oncology · 2017 · 2.7K citations · Full text

Checkmate 142, Medicine, Colorectal Cancer +8

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

Michael J. Overman, Sara Lonardi, Ka Yeung Mark Wong et al. · Journal of Clinical Oncology · 2018 · 2K citations · Full text

Immunology, Pathology, Immunotherapeutics +18

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

Sadhna Vora, Dejan Juric, Nayoon Kim et al. · Cancer Cell · 2014 · 428 citations · Full text

Pi3k Inhibitors, Breast Oncology, Medicine +10

An open-label, multicohort, phase I/II study of nivolumab in patients with virus-associated tumors (CheckMate 358): Efficacy and safety in recurrent or metastatic (R/M) cervical, vaginal, and vulvar cancers.

Antoine Hollebecque, Tim Meyer, Kathleen N. Moore et al. · Journal of Clinical Oncology · 2017 · 99 citations

Phase I/ii Study, Immunology, Immunoediting +21

Association of Tumor Mutational Burden with Efficacy of Pembrolizumab±Chemotherapy as First-Line Therapy for Gastric Cancer in the Phase III KEYNOTE-062 Study

Keun‐Wook Lee, Eric Van Cutsem, Yung‐Jue Bang et al. · Clinical Cancer Research · 2022 · 81 citations · Full text